[HTML][HTML] The clinical progress of mRNA vaccines and immunotherapies
The emergency use authorizations (EUAs) of two mRNA-based severe acute respiratory
syndrome coronavirus (SARS-CoV)-2 vaccines approximately 11 months after publication of …
syndrome coronavirus (SARS-CoV)-2 vaccines approximately 11 months after publication of …
New‐onset autoimmune phenomena post‐COVID‐19 vaccination
Y Chen, Z Xu, P Wang, XM Li, ZW Shuai, DQ Ye… - …, 2022 - Wiley Online Library
Abstract Coronavirus disease 2019 (COVID‐19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has led to an unprecedented setback for …
respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has led to an unprecedented setback for …
[HTML][HTML] Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
M Sadarangani, A Marchant… - Nature Reviews …, 2021 - nature.com
Most COVID-19 vaccines are designed to elicit immune responses, ideally neutralizing
antibodies (NAbs), against the SARS-CoV-2 spike protein. Several vaccines, including …
antibodies (NAbs), against the SARS-CoV-2 spike protein. Several vaccines, including …
[HTML][HTML] BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
U Sahin, A Muik, I Vogler, E Derhovanessian, LM Kranz… - Nature, 2021 - nature.com
Abstract BNT162b2, a nucleoside-modified mRNA formulated in lipid nanoparticles that
encodes the SARS-CoV-2 spike glycoprotein (S) stabilized in its prefusion conformation, has …
encodes the SARS-CoV-2 spike glycoprotein (S) stabilized in its prefusion conformation, has …
[HTML][HTML] COVID-19 vaccines
D Ndwandwe, CS Wiysonge - Current opinion in immunology, 2021 - Elsevier
Highlights•COVID-19 vaccine development has accelerated at an incredible rate with 105
vaccines in clinical development and 18 approved for emergency use.•This is the first time in …
vaccines in clinical development and 18 approved for emergency use.•This is the first time in …
[HTML][HTML] BNT162b vaccines protect rhesus macaques from SARS-CoV-2
AB Vogel, I Kanevsky, Y Che, KA Swanson, A Muik… - Nature, 2021 - nature.com
A safe and effective vaccine against COVID-19 is urgently needed in quantities that are
sufficient to immunize large populations. Here we report the preclinical development of two …
sufficient to immunize large populations. Here we report the preclinical development of two …
[HTML][HTML] A guide to vaccinology: from basic principles to new developments
AJ Pollard, EM Bijker - Nature Reviews Immunology, 2021 - nature.com
Immunization is a cornerstone of public health policy and is demonstrably highly cost-
effective when used to protect child health. Although it could be argued that immunology has …
effective when used to protect child health. Although it could be argued that immunology has …
[HTML][HTML] Pandemics throughout history
The emergence and spread of infectious diseases with pandemic potential occurred
regularly throughout history. Major pandemics and epidemics such as plague, cholera, flu …
regularly throughout history. Major pandemics and epidemics such as plague, cholera, flu …
[HTML][HTML] Coronavirus vaccine development: from SARS and MERS to COVID-19
Abstract Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a new type of
coronavirus that causes the Coronavirus Disease 2019 (COVID-19), which has been the …
coronavirus that causes the Coronavirus Disease 2019 (COVID-19), which has been the …
[HTML][HTML] COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
U Sahin, A Muik, E Derhovanessian, I Vogler, LM Kranz… - Nature, 2020 - nature.com
An effective vaccine is needed to halt the spread of the severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety, tolerability and …
coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety, tolerability and …